1. Home
  2. TBPH vs REAX Comparison

TBPH vs REAX Comparison

Compare TBPH & REAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • REAX
  • Stock Information
  • Founded
  • TBPH 2013
  • REAX 2018
  • Country
  • TBPH United States
  • REAX United States
  • Employees
  • TBPH N/A
  • REAX N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • REAX
  • Sector
  • TBPH Health Care
  • REAX
  • Exchange
  • TBPH Nasdaq
  • REAX Nasdaq
  • Market Cap
  • TBPH 699.0M
  • REAX 790.0M
  • IPO Year
  • TBPH N/A
  • REAX N/A
  • Fundamental
  • Price
  • TBPH $18.81
  • REAX $3.98
  • Analyst Decision
  • TBPH Strong Buy
  • REAX Strong Buy
  • Analyst Count
  • TBPH 4
  • REAX 3
  • Target Price
  • TBPH $24.25
  • REAX $6.33
  • AVG Volume (30 Days)
  • TBPH 569.5K
  • REAX 1.7M
  • Earning Date
  • TBPH 11-10-2025
  • REAX 10-30-2025
  • Dividend Yield
  • TBPH N/A
  • REAX N/A
  • EPS Growth
  • TBPH N/A
  • REAX N/A
  • EPS
  • TBPH 0.58
  • REAX N/A
  • Revenue
  • TBPH $80,327,000.00
  • REAX $1,813,907,000.00
  • Revenue This Year
  • TBPH $79.82
  • REAX $55.78
  • Revenue Next Year
  • TBPH N/A
  • REAX $22.39
  • P/E Ratio
  • TBPH $32.54
  • REAX N/A
  • Revenue Growth
  • TBPH 27.12
  • REAX 65.60
  • 52 Week Low
  • TBPH $7.90
  • REAX $3.42
  • 52 Week High
  • TBPH $18.96
  • REAX $5.65
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 68.84
  • REAX 55.00
  • Support Level
  • TBPH $17.50
  • REAX $3.43
  • Resistance Level
  • TBPH $18.58
  • REAX $3.70
  • Average True Range (ATR)
  • TBPH 0.99
  • REAX 0.19
  • MACD
  • TBPH 0.16
  • REAX 0.04
  • Stochastic Oscillator
  • TBPH 98.49
  • REAX 76.55

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About REAX The Real Brokerage Inc.

The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.

Share on Social Networks: